Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Vera Therapeutics, Inc. - Class A Common Stock (NQ:VERA)

39.96 UNCHANGED

Streaming Delayed Price Updated: 4:00 PM EDT, Mar 13, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	0
Open	39.96
Bid (Size)	15.99 (200)
Ask (Size)	63.93 (200)
Prev. Close	39.96
Today's Range	39.96 - 39.96
52wk Range	18.53 - 56.05
Shares Outstanding	44,261,109
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

This Fund Bet $200 Million on a Biotech Stock Up 50% as Kidney Disease Drug Targets July 7 FDA Decision ↗

March 13, 2026

Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.

Via The Motley Fool

Vertex Pharmaceuticals Surges 8.3% as Renal Breakthrough Sparks Market Rally

March 11, 2026

In a significant milestone for precision medicine, Vertex Pharmaceuticals (NASDAQ:VRTX) emerged as the top performer in the S&P 500 on March 11, 2026, with its shares climbing 8.3%. The rally followed...

Via MarketMinute

Performance

YTD	-17.8%	-17.8%
1 Month	-5.4%	-5.4%
3 Month	-18.8%	-18.8%
6 Month	+64.9%	+64.9%
1 Year	+42.4%	+42.4%

More News

Vertex Pharmaceuticals Surges as Breakthrough Kidney Data Sets New Gold Standard for IgA Nephropathy

March 10, 2026

Via MarketMinute

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 06, 2026

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Appoints Christopher Hite to Board of Directors

March 05, 2026

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

February 26, 2026

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics to Participate at Upcoming Investor Conferences

February 24, 2026

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 06, 2026

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

January 28, 2026

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

January 09, 2026

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

January 08, 2026

From Vera Therapeutics

Via GlobeNewswire

Why Vera Therapeutics Stock Zoomed Higher Today ↗

January 07, 2026

Via The Motley Fool

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

January 07, 2026

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

December 09, 2025

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

December 08, 2025

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 05, 2025

From Vera Therapeutics

Via GlobeNewswire

Why Vera Therapeutics Stock Rocked the Market on Tuesday ↗

December 02, 2025

Via The Motley Fool

Why Vera Therapeutics Stock Crushed it Today ↗

November 26, 2025

Via The Motley Fool

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

November 26, 2025

From Vera Therapeutics

Via GlobeNewswire

Get insights into the top gainers and losers of Tuesday's after-hours session. ↗

November 25, 2025

Via Chartmill

Vera Therapeutics to Participate at Upcoming Investor Conferences

November 24, 2025

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

November 10, 2025

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

November 07, 2025

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 07, 2025

From Vera Therapeutics

Via GlobeNewswire

Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine

November 06, 2025

From Vera Therapeutics

Via GlobeNewswire

Frequently Asked Questions

Is Vera Therapeutics, Inc. - Class A Common Stock publicly traded?

Yes, Vera Therapeutics, Inc. - Class A Common Stock is publicly traded.

What exchange does Vera Therapeutics, Inc. - Class A Common Stock trade on?

Vera Therapeutics, Inc. - Class A Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Vera Therapeutics, Inc. - Class A Common Stock?

The ticker symbol for Vera Therapeutics, Inc. - Class A Common Stock is VERA on the Nasdaq Stock Market

What is the current price of Vera Therapeutics, Inc. - Class A Common Stock?

The current price of Vera Therapeutics, Inc. - Class A Common Stock is 39.96

When was Vera Therapeutics, Inc. - Class A Common Stock last traded?

The last trade of Vera Therapeutics, Inc. - Class A Common Stock was at 03/13/26 04:00 PM ET

What is the market capitalization of Vera Therapeutics, Inc. - Class A Common Stock?

The market capitalization of Vera Therapeutics, Inc. - Class A Common Stock is 1.77B

How many shares of Vera Therapeutics, Inc. - Class A Common Stock are outstanding?

Vera Therapeutics, Inc. - Class A Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.